Sunday 18 October 2026
Export IKT’s income statement to Excel — free account
Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $260,500.00, up 111.1% from fiscal 2022. In the quarter to June 2026, EPS was flat and free cash flow fell 123.2%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
1.65
0.18
−9.84%
Follow IKT
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Piotroski F-Score |
— | — | — | 4 | 4 | 2 | 3 | — | — |
P/S ratio |
105.66 | 105.66 | 105.66 | 81.92 | 8.63 | 111.13 | 30.78 | — | — |
Altman Z-Score |
— | — | — | 5.62 | 2.99 | (2.14) | (8.82) | — | — |
Altman Z″-Score (non-manufacturers) |
— | (18.10) | (2,760.23) | 1.92 | 11.26 | (0.04) | (16.20) | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
P/Operating CF |
1,075.34 | 1,075.34 | 1,075.34 | (60.44) | (6.54) | (3.86) | (2.33) | — | — |
Beneish M-Score |
— | — | — | — | (0.05) | (0.15) | — | — | — |
P/B ratio |
0.00 | 0.00 | 0.00 | 5.85 | 0.70 | 0.65 | 0.73 | — | — |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 5.85 | 0.70 | 0.65 | 0.73 | — | — |
EV/Sales |
105.65 | 105.65 | 105.65 | 61.93 | (4.51) | (75.51) | (20.10) | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.95 | 0.51 | 0.26 | — | — |
EV/Operating CF |
(155.88) | (155.88) | (155.88) | (38.30) | 0.98 | 0.54 | 0.29 | — | — |
EV/FCF |
(155.88) | (155.88) | (155.88) | (38.30) | 0.98 | 0.53 | 0.29 | — | — |
Quick Ratio |
0.11 | 0.24 | 0.00 | 3.12 | 10.08 | 6.25 | 3.85 | 26.13 | 21.54 |
Current Ratio |
0.11 | 0.35 | 0.01 | 3.13 | 10.47 | 6.60 | 4.13 | 26.37 | 21.70 |
Net Debt/EBITDA |
(1.09) | 0.18 | 0.00 | 4.95 | 2.76 | 1.27 | 0.67 | 3.42 | 3.44 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(0.32) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
1.32 | 2.84 | 0.78 | 0.09 | 0.11 | 0.00 | 0.01 | 0.00 | 0.00 |
Operating CF/Net income |
0.29 | (0.33) | 0.06 | 0.40 | 0.97 | 0.96 | 0.95 | 0.70 | 0.58 |
Capex/Depreciation |
— | — | — | — | — | (36.31) | (0.08) | 0.00 | (0.22) |
Interest Coverage |
(26.22) | (70.04) | (229.76) | (95.87) | (742.02) | (243.34) | — | — | — |
| 39.31% | 194.01% | 217.27% | (107.58%) | (61.35%) | (60.74%) | (118.88%) | (52.00%) | (36.05%) | |
| (27.85%) | (151.24%) | (396.78%) | (38.43%) | (51.65%) | (53.57%) | (96.49%) | (48.66%) | (34.49%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
28.54% | 90.72% | 135.70% | (28.31%) | (38.49%) | (86.33%) | (175.45%) | (29.04%) | (28.09%) |
Average Days of Receivables |
32.02 | 42.71 | 0.00 | 404.66 | 12.96 | 118.02 | 0.00 | — | — |
Research and Development Expense of Revenue |
85.19% | 90.25% | 227.37% | 127.96% | 366.35% | 9,752.84% | 5,227.79% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
34.47% | 62.26% | 380.17% | 375.55% | 209.88% | 5,038.17% | 2,584.22% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 15.89% | 127.96% | 82.13% | 49.41% | 371.23% | 191.98% | 0.00% | 0.00% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.17 | 1.43 | 1.49 | 1.33 | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Earnings Yield |
(2.09%) | (2.09%) | (2.09%) | (5.08%) | (58.49%) | (131.05%) | (267.65%) | — | — |
Free Cash Flow Yield |
(0.64%) | (0.64%) | (0.64%) | (1.97%) | (53.40%) | (128.19%) | (225.75%) | — | — |
Revenue per Share |
0.20 | 3.02 | 0.82 | 0.51 | 1.02 | 0.03 | 0.04 | 0.00 | 0.00 |
Operating CF per Share |
(0.01) | 0.54 | (0.25) | (0.82) | (4.71) | (4.11) | (3.00) | (0.81) | (0.28) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.06) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.01) | 0.54 | (0.25) | (0.82) | (4.71) | (4.17) | (3.00) | (0.81) | (0.28) |
Cash per Share |
0.00 | 0.28 | 0.01 | 10.19 | 13.42 | 5.46 | 2.20 | 4.11 | 1.82 |
Shareholders Equity per Share |
(0.14) | (0.58) | (3.29) | 7.15 | 12.66 | 4.98 | 1.82 | 4.00 | 1.76 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.14) | (0.58) | (3.29) | 7.15 | 12.66 | 4.98 | 1.82 | 4.00 | 1.76 |
Free Cash Flow |
(0.13) | 0.72 | (0.34) | (1.13) | (14.30) | (17.59) | (18.10) | (19.15) | (27.80) |
Working Capital |
(1.53) | (2.37) | (4.22) | 10.06 | 38.42 | 20.68 | 10.77 | 94.72 | 171.81 |
Capital Expenditures |
— | — | — | — | — | (0.24) | (0.01) | — | (0.01) |
Net Current Asset Value |
(1.53) | (2.37) | (4.49) | 9.78 | 38.42 | 20.47 | 10.68 | 94.72 | 171.81 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.95 | 0.51 | 0.26 | — | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.97 | 0.05 | — | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | — | — | — | — | 0.03 | 2.42 | 0.56 | 0.00 |
Cash ROIC |
13.11% | (179.47%) | 7.57% | (4.76%) | (18.06%) | (39.91%) | (74.70%) | (9.95%) | (7.91%) |
Accounts Receivable Turnover |
6.31 | 12.36 | 0.00 | 1.12 | 7.01 | 1.65 | 0.00 | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | — | — | — |
Average Receivables |
0.33 | 0.33 | — | 0.62 | 0.44 | 0.08 | — | — | — |
Average Payables |
0.65 | 0.65 | 0.98 | 1.36 | 1.41 | 1.12 | 0.90 | 0.79 | 1.05 |
Average Assets |
1.57 | 1.42 | 1.44 | 7.41 | 28.63 | 33.70 | 19.72 | 56.55 | 139.90 |
Average Common Equity |
(1.11) | (1.11) | (2.63) | 2.65 | 24.10 | 29.73 | 16.01 | 52.92 | 133.89 |
Columns are period end dates